Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
7(35%)
Results Posted
13%(1 trials)
Terminated
1(5%)

Phase Distribution

Ph phase_4
1
5%
Ph early_phase_1
2
10%
Ph phase_2
7
35%
Ph not_applicable
10
50%

Phase Distribution

2

Early Stage

7

Mid Stage

1

Late Stage

Phase Distribution20 total trials
Early Phase 1First-in-human
2(10.0%)
Phase 2Efficacy & side effects
7(35.0%)
Phase 4Post-market surveillance
1(5.0%)
N/ANon-phased studies
10(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

72.7%

8 of 11 finished

Non-Completion Rate

27.3%

3 ended early

Currently Active

7

trials recruiting

Total Trials

20

all time

Status Distribution
Active(7)
Completed(8)
Terminated(3)
Other(2)

Detailed Status

Completed8
Recruiting4
Active, not recruiting3
Withdrawn2
unknown2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
20
Active
7
Success Rate
88.9%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (10.0%)
Phase 27 (35.0%)
Phase 41 (5.0%)
N/A10 (50.0%)

Trials by Status

recruiting420%
terminated15%
withdrawn210%
unknown210%
active_not_recruiting315%
completed840%

Recent Activity

Clinical Trials (20)

Showing 20 of 20 trials
NCT04276740Phase 2

MARVEL: Mitochondrial Anti-oxidant Therapy to Resolve Inflammation in Ulcerative Colitis

Active Not Recruiting
NCT05539625Phase 2

Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis

Withdrawn
NCT04851288Phase 2

Mitochondrial-targeted Antioxidant Supplementation for Improving Age-related Vascular Dysfunction in Humans

Active Not Recruiting
NCT05561556Not Applicable

Mitochondria Oxidative Stress and Vascular Health Study

Completed
NCT06429059Phase 2

ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments

Completed
NCT06191965Phase 2

MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction

Recruiting
NCT04109820Not Applicable

Effect of MitoQ on Platelet Function and Reactive Oxygen Species Generation in Patients With Sickle Cell Anemia

Recruiting
NCT03506633Not Applicable

Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients

Completed
NCT05686967Early Phase 1

MitoQ and Exercise Effects on Vascular Health

Active Not Recruiting
NCT05605548Early Phase 1

Mitochondrial Derived Reactive Oxygen Species on Cardiovascular Health in Chronic Obstructive Pulmonary Disease (COPD)

Terminated
NCT06424756Phase 2

Effects of an Antioxidant Supplement on Blood Vessel Health

Recruiting
NCT04334135Not Applicable

The Influence of Mitochondrial-Derived Reactive Oxygen Species on Racial Disparities in Neurovascular Function

Recruiting
NCT06069245Not Applicable

MitoQ & Cardiopulmonary Responses During Exercise

Completed
NCT03514875Not Applicable

Effects of Mitochondrial-targeted Antioxidant on Mild Cognitive Impairment (MCI) Patients

Withdrawn
NCT03960073Not Applicable

Chronic Kidney Disease and Heart Failure With Preserved Ejection Fraction: The Role of Mitochondrial Dysfunction

Completed
NCT04558190Not Applicable

Mitochondrial Dysfunction and Insulin Resistance in Skeletal Muscle

Completed
NCT04098510Not Applicable

Concentration of MitoQ in Human Skeletal Muscle

Unknown
NCT02364648Phase 4

Mitochondrial Oxidative Stress and Vascular Health in Chronic Kidney Disease

Unknown
NCT02597023Not Applicable

The Efficacy of Oral Mitoquinone (MitoQ) Supplementation for Improving Physiological in Middle-aged and Older Adults

Completed
NCT00329056Phase 2

A Trial of MitoQ for the Treatment of People With Parkinson's Disease

Completed

All 20 trials loaded

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
20